(0.50%) 5 071.75 points
(0.38%) 38 214 points
(0.63%) 17 547 points
(0.58%) $79.46
(1.09%) $1.953
(0.57%) $2 324.20
(0.10%) $26.78
(1.43%) $968.60
(0.04%) $0.933
(0.01%) $11.03
(-0.07%) $0.798
(-0.45%) $92.84
5.48% € 720.10
Live Chart Being Loaded With Signals
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...
Stats | |
---|---|
Tagesvolumen | 13 400.00 |
Durchschnittsvolumen | 6 602.00 |
Marktkapitalisierung | 684.65B |
EPS | €0 ( 2024-04-30 ) |
Last Dividend | €1.130 ( 2023-08-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 113.58 |
ATR14 | €1.722 (0.24%) |
Volumen Korrelation
Eli Lilly and Co Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Eli Lilly and Co Korrelation - Währung/Rohstoff
Eli Lilly and Co Finanzdaten
Annual | 2023 |
Umsatz: | €34.12B |
Bruttogewinn: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2023 |
Umsatz: | €34.12B |
Bruttogewinn: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2022 |
Umsatz: | €28.54B |
Bruttogewinn: | €21.91B (76.77 %) |
EPS: | €6.93 |
FY | 2021 |
Umsatz: | €28.32B |
Bruttogewinn: | €21.01B (74.18 %) |
EPS: | €5.83 |
Financial Reports:
No articles found.
Eli Lilly and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.980 (N/A) |
€0.980 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.490 | 2009-05-13 |
Last Dividend | €1.130 | 2023-08-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | €27.35 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 5.72 | |
Div.Growth Potential Score | 6.05 | |
Div. Directional Score | 5.89 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UWS.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
EBA.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
NN6.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
AAG.DE | Ex Dividend Junior | 2023-06-16 | Sporadic | 0 | 0.00% | |
G24.DE | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
PSG.DE | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
AXA.DE | Ex Dividend Junior | 2023-05-08 | Sporadic | 0 | 0.00% | |
HYI.F | No Dividend Player | 2023-06-19 | Annually | 0 | 0.00% | |
SOW.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
CMC.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0819 | 1.200 | 7.27 | 8.73 | [0 - 0.3] |
returnOnEquityTTM | 0.474 | 1.500 | 5.85 | 8.77 | [0.1 - 1] |
payoutRatioTTM | 0.777 | -1.000 | 2.23 | -2.23 | [0 - 1] |
currentRatioTTM | 0.943 | 0.800 | -0.287 | -0.230 | [1 - 3] |
quickRatioTTM | 0.523 | 0.800 | -1.632 | -1.305 | [0.8 - 2.5] |
cashRatioTTM | 0.103 | 1.500 | -0.537 | -0.806 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.43 | -5.15 | [0 - 0.6] |
interestCoverageTTM | 15.00 | 1.000 | 5.56 | 5.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.660 | -3.32 | [0 - 20] |
debtEquityRatioTTM | 2.34 | -1.500 | 0.633 | -0.949 | [0 - 2.5] |
grossProfitMarginTTM | 0.792 | 1.000 | 0.126 | 0.126 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.214 | 1.000 | 7.73 | 7.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.168 | 1.000 | -0.177 | -0.177 | [0.2 - 2] |
assetTurnoverTTM | 0.533 | 0.800 | 9.78 | 7.82 | [0.5 - 2] |
Total Score | 5.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 139.05 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.474 | 2.50 | 7.33 | 8.77 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.107 | -3.32 | [0 - 30] |
dividendYielPercentageTTM | 0.611 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.777 | 1.500 | 2.23 | -2.23 | [0 - 1] |
pegRatioTTM | 8.03 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.124 | 1.000 | 9.39 | 0 | [0.1 - 0.5] |
Total Score | 6.05 |
Eli Lilly and Co
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.